MARKET

PTPI

PTPI

PETROS PHARMACEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.620
-0.220
-7.75%
After Hours: 2.620 0 0.00% 19:59 01/14 EST
OPEN
2.710
PREV CLOSE
2.840
HIGH
2.800
LOW
2.530
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
5.20
52 WEEK LOW
1.190
MARKET CAP
43.10M
P/E (TTM)
-3.2458
1D
5D
1M
3M
1Y
5Y
5 Short Squeeze Candidates To Watch: Insignia Systems, American Virtual Cloud Top List Again, Reliance Global Rejoins
Potential short squeeze plays gained steam in 2021 with new retail traders looking for the next huge move.
Benzinga · 6d ago
Insider Weekends: Co-Founder Of EverQuote Acquires $1.45 Million Worth Of Stock
Reviewing the list of companies that were at a new 52 week high and the ones that had hit a fresh 52 week low last week, I was struck by just how many of the companies in the 52 week high list were financial/banking companies and from the energy sector. Si...
Benzinga · 01/09 17:17
Neville Rodie & Shaw Inc Buys Cleveland-Cliffs Inc, Palo Alto Networks Inc, Novo Nordisk ...
New York, NY, based Investment company Neville Rodie & Shaw Inc (Current Portfolio) buys Cleveland-Cliffs Inc, Palo Alto Networks Inc, Novo Nordisk A/S, United Rentals Inc, CAE Inc, sells , Verizon Communications Inc, Trane Technologies PLC, Lululemon Athl...
GuruFocus.com · 01/05 18:38
Watching Siyata Mobile, Petros Pharmaceuticals, SeaChange, Applied UV; Traders Circulate Report '4 Penny Stocks To Buy For Under $5 With High Short Interest'
https://pennystocks.com/featured/2022/01/03/4-penny-stocks-to-buy-for-under-5-with-high-short-interest/
Benzinga · 01/03 15:13
5 Short Squeeze Candidates To Watch: Insignia Systems Tops List With High Cost To Borrow, SeaChange Joins
Potential short squeeze plays gained steam in 2021 with new retail traders looking for the next huge move.
Benzinga · 01/03 15:10
How Is The Market Feeling About Petros Pharmaceuticals Inc?
Petros Pharmaceuticals Inc. - Common Stock's (NASDAQ:PTPI) short percent of float has risen 527.05% since last its last report. The company recently reported that it has 2.14 million shares sold short, which is 55.87% of all regular shares that are availab...
Benzinga · 12/31/2021 18:11
Petros Pharma gains after announcing completion of capital raise
The micro-cap pharma company, Petros Pharmaceuticals (PTPI +7.0%) is rising for the third straight session after disclosing the completion of its previously announced direct offering and private placement. Petros (NASDAQ:PTPI)
Seekingalpha · 12/28/2021 19:13
ISIG, CPOP and BFRI among mid-day movers
Gainers: Insignia Systems (NASDAQ:ISIG) +83%.. Pop Culture (NASDAQ:CPOP) +24%. Regencell Bioscience RGC +20% BridgeBio Pharma BBIO +19%. Gamida Cell (NASDAQ:GMDA) +17%. ADDvantage Technologies (NASDAQ:AEY) +17%. Centogene (NASDAQ:CNTG) +14% Altamira Therap...
Seekingalpha · 12/28/2021 17:52
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTPI. Analyze the recent business situations of PETROS PHARMACEU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About PTPI
Petros Pharmaceuticals, Inc. is a pharmaceutical company that is focused on men’s health therapeutics with a range of commercial capabilities, including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing and distribution. Its Stendraas is the United States Food and Drug Administration (FDA) approved phosphodiesterase 5 (PDE-5) inhibitor prescription medication for the treatment of erectile dysfunction (ED) and is the only patent-protected PDE-5 inhibitor on the market. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products of the Company are committed to identifying and developing other pharmaceuticals to advance men’s health, which is H100, which is the topical formulation candidate for the treatment of acute Peyronie’s disease.

Webull offers kinds of Petros Pharmaceuticals Inc stock information, including NASDAQ:PTPI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTPI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTPI stock methods without spending real money on the virtual paper trading platform.